Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Nervous system disease

Laquinimod inhibits secondary progressive MS in mouse model

Laquinimod reduced the number of mice who developed multiple sclerosis in one model, and slowed disease progression in another.

MRI scan of brain with multiple sclerosis (MS)

Source: Pr Michel Brauner / Science Photo Library

Multiple sclerosis (pictured in brain scan) was found to progress more slowly and develop less frequently in mice given the drug laquinimod

Findings from phase III trials of drug candidate laquinimod in relapsing-remitting multiple sclerosis (MS) have indicated that it could be beneficial in reducing disease progression.

Therefore, researchers studied the effect of laquinimod compared with placebo in two mouse models of secondary progressive MS — a harder-to-treat form of the disease.

The drug reduced the number of mice who developed MS in one of the models and in the other, in which mice were given laquinimod after symptoms developed, slowed progression of the disease.

The results showed that laquinimod modulated immune responses and, in particular, suppressed the development of meningeal B cell aggregates, which may be associated with progression in secondary MS.

Reporting in Neurology: Neuroimmunology & Neuroinflammation (online, 21 September 2016)[1], the researchers say the findings give insight into the potential application of laquinimod in the treatment of MS.

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2016.20201752

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • MRI scan of brain with multiple sclerosis (MS)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.